Subsequent Survival and Loss of Lifetime for Patients With Progression-Free 24 Months After Treatment in Nasopharyngeal Carcinoma: A Comprehensive Nationwide Population-Based Analysis

Abstract

Currently, there is little evidence supporting the use of early endpoints to assess primary treatment outcomes in nasopharyngeal carcinoma (NPC). We aim to explore the relationship between 24-month progression-free survival (PFS24) and subsequent overall survival (sOS) as well as loss of lifetime (LoL) in NPC patients. sOS is defined as survival from the 24-month point or progression within 24 months leading to mortality. LoL represents the reduction in life expectancy due to NPC, compared to the general population matched by age, sex, and calendar year. The standardized mortality ratio (SMR) is defined as the ratio of observed mortality to expected mortality. The study included 6315 patients from nonendemic and endemic regions of China. Among them, 5301 patients (83.9%) achieved PFS24, with a 5-year sOS of 90.2% and an SMR of 1.0. Over a 10-year period following treatment, the mean LoL was only 0.01 months/year. For most subgroups, patients achieving PFS24 exhibited comparable sOS and LoL with the general population. However, patients failing to achieve PFS24 showed significantly worse outcomes, with 5-year sOS of 21.9%, SMR of 23.7, and LoL of 6.48 months/year. These notable outcome disparities highlight the importance of PFS24 in NPC risk stratification, patient monitoring, and study design.

Keywords

early recurrence / loss of lifetime / nasopharyngeal carcinoma / standardized mortality ratio / subsequent survival / surrogate endpoint

References

[1] K. H. Au, R. K. C. Ngan, A. W. Y. Ng, et al., “Treatment Outcomes of Nasopharyngeal Carcinoma in Modern Era After Intensity Modulated Radiotherapy (IMRT) in Hong Kong: A Report of 3328 Patients (HKNPCSG 1301 Study),” Oral Oncology 77 (2018): 16-21.

[2] W. T. Ng, J. Corry, J. A. Langendijk, et al., “Current Management of Stage IV Nasopharyngeal Carcinoma Without Distant Metastasis,” Cancer Treatment Reviews 85 (2020): 101995.

[3] L. H. Jakobsen, M. Bogsted, P. N. Brown, et al., “Minimal Loss of Lifetime for Patients with Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study,” Journal of Clinical Oncology 35, no. 7 (2017): 778-784.

[4] M. J. Maurer, T. M. Habermann, Q. Shi, et al., “Progression-Free Survival at 24 Months (PFS24) and Subsequent Outcome for Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials,” Annals of Oncology 29, no. 8 (2018): 1822-1827.

[5] M. J. Maurer, F. Ellin, L. Srour, et al., “International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma,” Journal of Clinical Oncology 35, no. 36 (2017): 4019-4026.

[6] Y. Yang, Y. Wang, X. Liu, et al., “Progression-Free Survival at 24 Months and Subsequent Survival of Patients With Extranodal NK/T-Cell Lymphoma: A China Lymphoma Collaborative Group (CLCG) Study,” Leukemia 35, no. 6 (2021): 1671-1682.

[7] L. Q. Tang, C. F. Li, J. Li, et al., “Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma,” JNCI: Journal of the National Cancer Institute 108, no. 1 (2016): djv291.

[8] R. Guo, L. L. Tang, Y. P. Mao, et al., “Proposed Modifications and Incorporation of Plasma Epstein-Barr Virus DNA Improve the TNM Staging System for Epstein-Barr Virus-Related Nasopharyngeal Carcinoma,” Cancer 125, no. 1 (2019): 79-89.

[9] V. H. Lee, D. L. Kwong, T. W. Leung, et al., “The Addition of Pretreatment Plasma Epstein-Barr Virus DNA Into the Eighth Edition of Nasopharyngeal Cancer TNM Stage Classification,” International Journal of Cancer 144, no. 7 (2019): 1713-1722.

[10] J. J. Pan, W. T. Ng, J. F. Zong, et al., “Prognostic Nomogram for Refining the Prognostication of the Proposed 8th Edition of the AJCC/UICC Staging System for Nasopharyngeal Cancer in the Era of Intensity-Modulated Radiotherapy,” Cancer 122, no. 21 (2016): 3307-3315.

[11] W. Liang, G. Shen, Y. Zhang, et al., “Development and Validation of a Nomogram for Predicting the Survival of Patients With Non-Metastatic Nasopharyngeal Carcinoma After Curative Treatment,” Chinese Journal of Cancer 35, no. 1 (2016): 98.

[12] C. Xu, Y. P. Chen, X. Liu, et al., “Establishing and Applying Nomograms Based on the 8th Edition of the UICC/AJCC Staging System to Select Patients With Nasopharyngeal Carcinoma Who Benefit From Induction Chemotherapy Plus Concurrent Chemoradiotherapy,” Oral Oncology 69 (2017): 99-107.

[13] L. L. Tang, Y. P. Chen, Y. P. Mao, et al., “Validation of the 8th Edition of the UICC/AJCC Staging System for Nasopharyngeal Carcinoma from Endemic Areas in the Intensity-Modulated Radiotherapy Era,” Journal of the National Comprehensive Cancer Network: JNCCN 15, no. 7 (2017): 913-919.

[14] J. Wang, X. Huang, S. Sun, et al., “Stage-Dependent Conditional Survival and Failure Hazard of Non-metastatic Nasopharyngeal Carcinoma After Intensity-Modulated Radiation Therapy: Clinical Implications for Treatment Strategies and Surveillance,” Cancer Medicine 10, no. 11 (2021): 3613-3621.

[15] N. Portolani, A. Coniglio, S. Ghidoni, et al., “Early and Late Recurrence After Liver Resection for Hepatocellular Carcinoma: Prognostic and Therapeutic Implications,” Annals of Surgery 243, no. 2 (2006): 229-235.

[16] K. Imai, M. A. Allard, C. C. Benitez, et al., “Early Recurrence After Hepatectomy for Colorectal Liver Metastases: What Optimal Definition and What Predictive Factors?,” Oncologist 21, no. 7 (2016): 887-894.

[17] X. F. Zhang, E. W. Beal, J. Chakedis, et al., “Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-Intent Surgery: A Multi-Institutional Study From the US Extrahepatic Biliary Malignancy Consortium,” World Journal of Surgery 42, no. 9 (2018): 2919-2929.

[18] X. L. Yang, L. L. Zhang, J. Kou, et al., “Cisplatin-Based Concurrent Chemoradiotherapy Improved the Survival of Locoregionally Advanced Nasopharyngeal Carcinoma After Induction Chemotherapy by Reducing Early Treatment Failure,” BMC Cancer 22, no. 1 (2022): 1230.

[19] L. L. Zhang, W. H. Zheng, W. J. Zhu, et al., “Prognostic Models for Early and Late Tumor Progression Prediction in Nasopharyngeal Carcinoma: An Analysis of 8292 Endemic Cases,” Cancer Medicine 12, no. 5 (2023): 5384-5396.

[20] Y. P. Chen, Y. Sun, L. Chen, et al., “Surrogate Endpoints for Overall Survival in Combined Chemotherapy and Radiotherapy Trials in Nasopharyngeal Carcinoma: Meta-Analysis of Randomised Controlled Trials,” Radiotherapy and Oncology 116, no. 2 (2015): 157-166.

[21] F. Rotolo, J. P. Pignon, J. Bourhis, et al., “Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-Analysis,” JNCI: Journal of the National Cancer Institute 109, no. 4 (2017): djw239.

[22] S. Zhou, C. Chen, S. R. Liu, et al., “Surrogate Endpoints Shortening the Therapeutic Evaluation Duration for Different Subgroups of Patients With Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy: A Retrospective Analysis of 830 Patients Stratified by the 8th Edition of the UICC/AJCC Staging System and Plasma Epstein-Barr Viral,” Journal of Cancer 9, no. 18 (2018): 3352-3360.

[23] A. W. M. Lee, V. H. F. Lee, W. T. Ng, et al., “A Systematic Review and Recommendations on the Use of Plasma EBV DNA for Nasopharyngeal Carcinoma,” European Journal of Cancer 153 (2021): 109-122.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.